Disease | li-fraumeni syndrome |
Comorbidity | C0001418|adenocarcinomas |
Sentences | 1 |
PubMedID- 25926079 | Development of novel therapies to battle lung cancer has been greatly aided by the emergence of genetically engineered mouse models (gemms) of lung cancer, such as the k-rasg12d;p53frt/frt non–small cell lung carcinoma (nsclc) model [3], where the compound effect of conditional mutations in the k-ras oncogene and the p53 tumor suppressor gene leads to development of adenocarcinomas in the mouse lung [4]. |
Page: 1